Literature DB >> 9917121

Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection.

M E Villarino1, W Burman, Y C Wang, L Lundergan, A Catanzaro, N Bock, C Jones, C Nolan.   

Abstract

CONTEXT: One or both commercial tuberculin skin test reagents (Aplisol and Tubersol) may have a high rate of false-positive reactions.
OBJECTIVE: To compare the reaction size and specificity of skin testing with Aplisol, Tubersol, and the standard purified protein derivative (PPD-S1).
DESIGN: Double-blind trial, conducted between May 14, 1997, and October28, 1997, in which each individual received 4 tuberculin skin reagents at sites assigned at random.
SETTING: Health departments and universities in 6 US cities. PARTICIPANTS: A total of 1555 persons at low risk of latent tuberculosis infection. INTERVENTION: Simultaneous skin tests with Aplisol, Tubersol, PPD-S1, and either a second PPD-S1 or PPD-S2 (a proposed new standard). MAIN OUTCOME MEASURE: Reaction size at each injection site measured by 2 investigators blinded to type of reagent.
RESULTS: Aplisol produced slightly larger reactions than Tubersol, but this difference did not significantly change skin test interpretation. The mean +/- SD reaction sizes were 3.4+/-4.2 mm with Aplisol, 2.1+/-3.2 mm with Tubersol, and 2.5+/-3.6 mm with PPD-S1. Assuming that all participants were uninfected and using a 10-mm cutoff, the specificities of the tests were high: Aplisol, 98.2%; Tubersol, 99.2%; and PPD-S1, 98.9%. Significant variability was not detected in interobserver, host, and lot-to-lot reagent comparisons.
CONCLUSION: Using a cutoff of at least 10 mm, testing with 3 different PPD reagents resulted in similar numbers of uninfected persons being correctly classified.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9917121     DOI: 10.1001/jama.281.2.169

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  7 in total

1.  Differences in tuberculin reactivity as determined in a veterans administration employee health screening program.

Authors:  Sanjay R Mehta; Cathy MacGruder; David Looney; Scott Johns; Davey M Smith
Journal:  Clin Vaccine Immunol       Date:  2009-02-18

2.  Diagnosis and treatment of latent tuberculosis infection: an update.

Authors:  Anna K Person; April C Pettit; Timothy R Sterling
Journal:  Curr Respir Care Rep       Date:  2013-12

Review 3.  Purified protein derivatives of tuberculin--past, present, and future.

Authors:  Hongliang Yang; Nicole A Kruh-Garcia; Karen M Dobos
Journal:  FEMS Immunol Med Microbiol       Date:  2012-08-01

4.  Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda.

Authors:  Carina Marquez; Gabriel Chamie; Jane Achan; Anne F Luetkemeyer; Mary Kyohere; Jaffer Okiring; Grant Dorsey; Moses R Kamya; Edwin D Charlebois; Diane V Havlir
Journal:  Pediatr Infect Dis J       Date:  2016-05       Impact factor: 2.129

5.  Nationwide Shortage of Tuberculin Skin Test Antigens: CDC Recommendations for Patient Care and Public Health Practice.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-06-21       Impact factor: 17.586

6.  The single recombinant M. tuberculosis protein DPPD provides enhanced performance of skin testing among HIV-infected tuberculosis patients.

Authors:  Roberto Badaro; Bruna A S Machado; Malcolm S Duthie; C A Araujo-Neto; D Pedral-Sampaio; Maria Nakatani; Steven G Reed
Journal:  AMB Express       Date:  2020-07-31       Impact factor: 3.298

Review 7.  Skin tests for the detection of Mycobacterial infections: achievements, current perspectives, and implications for other diseases.

Authors:  Malcolm S Duthie; Steven G Reed
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-04       Impact factor: 4.813

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.